Breast Imaging

What Is the Next Imaging Step for an Indeterminate Male Breast Mass After Mammography?

·
What Is the Next Imaging Step for an Indeterminate Male Breast Mass After Mammography?

A 45-year-old male is in your clinic for follow-up. He felt a small, firm lump in his left breast a few weeks ago. You ordered a diagnostic mammogram, and the report just arrived: an indeterminate, focal asymmetry that the radiologist has categorized as suspicious. The patient is understandably anxious, and you need to determine the most direct and effective next step to characterize this finding. This is not a time for guesswork; it is a time for a precise, evidence-based workflow.

This article provides a focused, deep-dive into the American College of Radiology (ACR) Appropriateness Criteria for this exact clinical scenario: a male patient, 25 or older, with an indeterminate or suspicious finding on mammography for a palpable breast mass. The definitive next step, rated Usually Appropriate by the ACR, is a targeted breast ultrasound.

Who Fits This Clinical Scenario?

This workflow is specifically for an adult male patient, aged 25 or older, who has already undergone initial imaging for a palpable breast mass. The key inclusion criteria are:

  • Patient: Male, 25 years of age or older.
  • Symptom: A palpable breast mass that feels indeterminate on physical examination (i.e., not clearly benign or malignant).
  • Prior Imaging: A diagnostic mammogram or digital breast tomosynthesis (DBT) has been performed and the result is indeterminate (BI-RADS 0), suspicious (BI-RADS 4), or highly suggestive of malignancy (BI-RADS 5).

It is crucial to distinguish this situation from other common presentations. This guidance does not apply if:

  • The initial imaging has not yet been performed. The workup for a palpable mass in a male over 25 begins with mammography. This article addresses the step after that initial mammogram is inconclusive.
  • The patient is younger than 25. For younger men, ultrasound is often considered the initial imaging modality of choice, representing a different branch of the ACR guidelines.
  • The physical exam is classic for gynecomastia. If a patient presents with bilateral, symmetric, tender, concentric subareolar tissue, and no other suspicious features, imaging may not be necessary at all.
  • The physical exam is highly suspicious for cancer. In cases with clear signs of malignancy like skin ulceration, nipple retraction, or a fixed, hard mass with axillary adenopathy, the workflow may be accelerated directly toward biopsy, often guided by imaging.

What Diagnoses Are You Working Up in This Scenario?

When a mammogram for a palpable male breast mass is indeterminate or suspicious, the primary goal of subsequent imaging is to differentiate between benign and malignant causes. The differential diagnosis is focused and consequential.

Male Breast Cancer: This is the most critical diagnosis to exclude. While male breast cancer accounts for less than 1% of all breast cancers, its incidence increases with age. An indeterminate or suspicious mammographic finding, such as a spiculated mass, focal asymmetry, or suspicious microcalcifications, makes invasive ductal carcinoma the primary concern. The goal of the next imaging step is to characterize the lesion to determine if a tissue diagnosis via biopsy is warranted.

Focal or Asymmetric Gynecomastia: Gynecomastia is the most common cause of a palpable male breast mass. While it often appears as a classic flame-shaped or nodular density on mammography, atypical presentations can mimic malignancy, leading to an indeterminate reading. It can present as a focal asymmetry or mass-like density, making further characterization essential to avoid unnecessary biopsy of a benign condition.

Other Benign Masses: Though less common in men, other benign entities can present as palpable masses with non-specific mammographic features. These include lipomas, epidermal inclusion cysts, hematomas (especially with a history of trauma), and pseudoangiomatous stromal hyperplasia (PASH). Each has features that can be better characterized with further imaging.

Metastasis: In rare cases, a breast mass in a male can represent a metastasis from another primary cancer, such as lymphoma, melanoma, or lung carcinoma. These often appear as well-circumscribed round masses on mammography, which can be indeterminate without further evaluation.

Why Is Breast Ultrasound the Recommended Study for This Presentation?

After an indeterminate or suspicious mammogram, the ACR designates US breast as Usually appropriate. This is the definitive, evidence-based next step for several key reasons. Ultrasound excels at clarifying the findings that make a mammogram indeterminate.

First, ultrasound is highly effective at differentiating solid from cystic masses. A simple cyst identified on ultrasound that corresponds to the palpable and mammographic finding is definitively benign, concluding the workup. If the mass is solid, ultrasound provides critical information about its morphology that is superior to mammography. It can clearly delineate the lesion’s shape (oval vs. irregular), orientation, margins (circumscribed vs. spiculated), and internal echo pattern. These features are paramount in assessing the likelihood of malignancy and are used to assign a BI-RADS category to the ultrasound finding.

Second, ultrasound is the ideal modality for guiding a percutaneous biopsy. If the ultrasound confirms a suspicious solid mass (BI-RADS 4 or 5), the radiologist can perform a core needle biopsy under real-time sonographic guidance during the same visit. This is a fast, accurate, and minimally invasive procedure that provides a definitive tissue diagnosis, directly guiding subsequent management.

In contrast, other advanced imaging modalities are rated lower for this specific clinical question:

  • MRI breast without and with IV contrast: Rated Usually not appropriate. While breast MRI is extremely sensitive for detecting cancer, its specificity is lower. Using it at this stage can lead to the detection of incidental, non-specific enhancing foci, resulting in false positives, increased patient anxiety, and potentially unnecessary biopsies. Its primary role is in staging confirmed cancer or as a problem-solving tool in complex cases where mammography and ultrasound are discordant, not as the primary tool to characterize an indeterminate mammographic finding.
  • MRI breast without IV contrast: Also rated Usually not appropriate. A non-contrast breast MRI provides no clinically useful information for cancer detection or characterization and should not be ordered for this indication.

From a safety perspective, ultrasound is the optimal choice. It involves no ionizing radiation (adult radiation relative level: 0 mSv) and does not require intravenous contrast, avoiding any risk of allergic reaction or contrast-induced nephropathy.

What’s Next After Breast Ultrasound? Downstream Workflow

The results of the targeted breast ultrasound will dictate the subsequent steps. The goal is to achieve concordance, where the ultrasound finding explains the palpable lump and the indeterminate mammogram.

  • If the US is suspicious (BI-RADS 4 or 5): The finding is considered suspicious for malignancy. The clear next step is an ultrasound-guided core needle biopsy to obtain a tissue diagnosis. This is often performed by the radiologist at the time of the diagnostic ultrasound.
  • If the US shows a definitively benign finding (BI-RADS 2): This could be a simple cyst, a classic lipoma, or typical features of gynecomastia that fully explain the mammographic and palpable finding. In this case, the workup is complete, and the patient can be reassured. No further imaging is needed.
  • If the US is probably benign (BI-RADS 3): This is an uncommon outcome in this scenario but may occur. It implies a very low likelihood of malignancy (less than 2%). The standard recommendation is for short-interval imaging follow-up, typically with ultrasound in 6 months, to ensure stability.
  • If the US is negative or non-contributory (BI-RADS 1): This creates a critical situation known as radiologic-pathologic discordance. The suspicious finding on the mammogram remains unexplained. Dismissing the mammographic concern would be a clinical error. In this case, the next step is typically a mammographically-guided (stereotactic) biopsy of the original finding. An MRI may be considered in select cases, but direct tissue sampling of the mammographic target is usually preferred.

Pitfalls to Avoid (and When to Get Help)

Navigating this workflow requires careful attention to detail. Here are several common pitfalls to avoid:

  • Accepting a Discordant Result: Never dismiss a suspicious mammogram (BI-RADS 4/5) just because a targeted ultrasound is reported as negative (BI-RADS 1). The finding seen on the mammogram must be explained. If it isn’t, escalate the case by speaking directly with the radiologist to plan for a mammographically-guided biopsy.
  • Vague Clinical Information: When ordering the ultrasound, be precise. Clearly state the location of the palpable mass (e.g., “palpable lump, left breast, 2 o’clock, 3 cm from nipple”) and reference the prior mammogram. This ensures the sonographer and radiologist are targeting the correct area.
  • Stopping at “Gynecomastia”: While gynecomastia is common, breast cancer can coexist within or adjacent to it. If the mammographic features are atypical or suspicious, a simple diagnosis of “gynecomastia” on ultrasound may not be sufficient without a thorough evaluation to exclude a concurrent suspicious mass.
  • Prematurely Ordering MRI: Do not order a breast MRI to work up an indeterminate mammogram. It is not the right tool for initial characterization and can muddy the clinical picture with false positives. Stick to the proven workflow: mammogram → ultrasound → biopsy.

Related ACR Topics and Tools

This article covers a single, specific clinical scenario. For a comprehensive overview of all variants and initial imaging recommendations, or to explore the tools used to develop these guidelines, please refer to the following resources.

Frequently Asked Questions

Why not just biopsy the finding seen on the mammogram directly?

If a finding is visible on ultrasound, an ultrasound-guided biopsy is preferred over a mammographically-guided (stereotactic) biopsy. Ultrasound guidance is faster, does not involve radiation, does not require breast compression, and is generally more comfortable for the patient. A stereotactic biopsy is reserved for findings that are only visible on mammography.

What does a BI-RADS 4 or 5 category on the initial mammogram mean for the patient?

BI-RADS (Breast Imaging Reporting and Data System) is a standardized way to report imaging findings. BI-RADS 4 means the finding is ‘Suspicious,’ with a wide range of malignancy risk (2% to 95%). BI-RADS 5 means ‘Highly Suggestive of Malignancy,’ with a risk of 95% or greater. In either case, a tissue diagnosis is required, and the workflow described here—ultrasound for characterization and biopsy guidance—is the next step.

If the patient has gynecomastia, can he still get breast cancer?

Yes. While gynecomastia itself is a benign proliferation of glandular tissue, breast cancer can arise independently within the breast. Furthermore, some risk factors for gynecomastia, such as Klinefelter syndrome or estrogen excess, are also risk factors for male breast cancer. Therefore, any suspicious or atypical feature in a man with gynecomastia must be fully evaluated.

Does a family history of female breast cancer change this specific workflow?

A strong family history of breast cancer (especially with BRCA mutations) increases a man’s lifetime risk of developing breast cancer. However, for the specific scenario of working up an already-identified indeterminate mass on a mammogram, the diagnostic workflow remains the same: targeted ultrasound followed by biopsy if indicated. The family history adds to the clinical suspicion but does not change the sequence of diagnostic tests.

What if the ultrasound shows multiple other benign-appearing findings?

The primary goal of the ultrasound is to evaluate the specific area corresponding to the palpable and mammographic concern. If other incidental, clearly benign findings like simple cysts are noted elsewhere, they are typically documented as such (BI-RADS 2) and do not require further workup or alter the management of the primary suspicious lesion.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026